Alexipharmacopeia

The Washington Post article “FDA Delay In Cancer Therapy Is Attacked” reports that researchers Howard Scher and Maha Hussain feared for their safety at the recent ASCO meeting.

The two doctors have been at the center of an unusually bitter debate over an experimental therapy for prostate cancer, ever since they helped persuade the Food and Drug Administration to delay approving it, enraging both patients and investors. The first-of-its-kind therapy, called Provenge, is a “vaccine” designed to extend the lives of patients with advanced prostate cancer by stimulating their immune systems.

Dr. Scher’s letter is reprinted and discussed on the PSA Rising Blog.